LifeSci Capital Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
LifeSci Capital's Oliver McCammon maintains a Buy rating for Janux Therapeutics Inc with a $60 price target. McCammon, who covers the Healthcare sector, has an average return of 114.4% and a 53.13% success rate. Clear Street's Kaveri Pohlman also issued a Buy rating, while TR | OpenAI – 4o reiterated a Hold rating. The report highlights TipRanks' Cyber Monday sale offering 60% off Premium subscriptions.
In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Janux Therapeutics Inc, with a price target of $60.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
McCammon covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Perspective Therapeutics, and Corbus Pharmaceuticals. According to TipRanks, McCammon has an average return of 114.4% and a 53.13% success rate on recommended stocks.
In addition to LifeSci Capital, Janux Therapeutics Inc also received a Buy from Clear Street’s Kaveri Pohlman in a report issued on December 2. However, on December 3, TR | OpenAI – 4o reiterated a Hold rating on Janux Therapeutics Inc (NASDAQ: JANX).
